IMCAS 2026: Galderma Showcases the Latest Scientific Advances Behind the Industry’s Broadest Injectable Aesthetics Portfolio

(BUSINESS WIRE) -- Galderma (SIX: GALD) will present ten posters with the latest updates from across its broad aesthetic portfolio spanning regenerative biostimulation, HA and neuromodulator treatments at the International Master Course on Aging Science (IMCAS) 2026 World Congress in Paris, France, from January 29-31, 2026. The company will also showcase its leadership in community education through a number of events including two symposia, a live anatomy workshop, multiple masterclasses and meet-the-expert sessions, and a booth that will delve into the science behind its innovations.

Biostimulation: Sculptra’s innovative approach to regenerative aesthetics for the face and body backed by experts
In response to patients increasingly seeking harmony between facial and body aesthetics, Galderma recently announced the EU MDR certification of Sculptra, the first proven regenerative biostimulator, expanding its current clinical use to the body.³ At IMCAS, guidance developed by 13 international experts on Sculptra’s four MDR-approved indications – the gluteal area, posterior thighs, décolletage, and upper arms – will be presented.¹ The experts concluded that Sculptra’s benefits can be complemented with Restylane Skinboosters in the décolletage for comprehensive body rejuvenation, and recommended injection volumes for Sculptra to be used in the posterior thighs, upper arms and gluteal area to improve aesthetic appearance, including skin firmness and reduced appearance of cellulite.¹

Results from an expert review of data on Sculptra will also be presented, providing additional evidence of its regenerative properties.² This includes fibroblast activation leading to stimulation of collagen, elastin and other proteins involved in extracellular matrix regeneration and adipogenesis (the formation of healthy fat cells).² This clinically presents as long-term improvements such as increased volume, elasticity, and skin thickness.²

A final poster will examine the ease of Sculptra’s reconstitution process compared with two other poly-L-lactic acid biostimulators, finding that healthcare professionals had a strong preference for Sculptra’s reconstitution process and positively rated its speed of administration from preparation to injection.¹³

HA treatments: The Restylane range demonstrates its versatility in meeting diverse patient needs
Data from across Galderma’s portfolio of Restylane HA treatments will be presented supporting its versatile use on the face and décolletage, with a range of gel formulations to meet personalized needs from providing structural support to smoothing lines and wrinkles:

• The ARTIST post-marketing study found that Restylane Shaype, powered by new NASHA HD™ technology, is a safe and effective treatment for shaping the chin with natural-looking results, alone or in combination with Restylane Defyne™ and Restylane Lyft to provide lift, shape, and definition for diverse aesthetic needs.⁸ The poster also supports that Restylane Shaype has the highest G-prime (a measure of firmness) compared with other HA treatments produced with different manufacturing technologies, allowing for greater correction with lower injection volumes.⁸

• A study of Restylane Lyft for jawline definition showed it was effective and safe, and resulted in high subject satisfaction and aesthetic improvement through 12 months.⁹

• A study evaluating the effectiveness and safety of Restylane Skinboosters for correction of moderate-to-severe wrinkles in the décolletage found that it was well tolerated and highly efficacious with a significant improvement through Week 32 and high patient satisfaction.¹⁰

• A study of Restylane Volyme showed that it was safe and effective for correction of temple hollowing, with high and sustained results through Month 18 and high patient satisfaction.¹¹

Neuromodulation: Supporting Relfydess’ next-generation performance
Results will be presented from an analysis of wrinkle morphology and dynamic skin strain in the RELAX and EXPRESSION trials investigating Relfydess – the first and only ready-to-use liquid neuromodulator created with PEARL^TM Technology.^12,14 Results reinforce its onset of action as early as Day 1 in patients with moderate-to-severe frown lines and crow’s feet, with sustained improvements for six months.¹² Expert-led consensus recommendations will also be shared addressing important unmet needs in real-world clinical practice and providing clear guidance for the practical use of Relfydess, helping healthcare professionals select the optimal treatment protocol for their patients.¹⁵

Spearheading community education and awareness around unmet patient needs
Galderma will also present findings from a global survey of over 4,300 women across five continents linking menopause to several skin changes, including wrinkles, loss of firmness, dryness and dull skin, and the potential role of aesthetic treatments to address them.^16,17 As part of its response to this, Galderma will host a symposium titled ‘Menopause in the Mirror: Challenges, Science and Aesthetic Solutions’ on Friday, January 30 at 10:30 AM – 12:30 PM CET in Grand Amphi - Level 1.

A second symposium, titled ‘Exploring Breakthroughs in Injectable Regeneration for the Face, Body, and Skin Health’ will delve into the growing demand for holistic regenerative aesthetic solutions and take place on Thursday January 29 at 1:30 – 2:30 PM CET in Room 251, Level 2.

More information about Galderma’s activities at IMCAS 2026 can be found here.

About Sculptra
Sculptra is the first proven regenerative biostimulator, with a unique poly-L-lactic acid (PLLA-SCA™) formulation, to provide progressive and sustained regenerative effect across all three skin layers.^3,18-24 Sculptra reverses aging processes in the skin, including degradation of the extracellular matrix, which results in volume loss, laxity, and the appearance of wrinkles.^{3,18,19,25-27} Sculptra progressively rebuilds the skin’s structural foundation by encouraging the remodeling of components of the extracellular matrix, such as elastin and collagen, helping to gradually restore volume, firmness, radiance and skin quality, and the look of fullness to wrinkles and folds over time.^3-7,18,19,28 Sculptra has been shown to provide visible improvements as early as one month after treatment, with results lasting up to two years.^3,6,23,28,29

About the Restylane portfolio
Restylane HA treatments are designed differently to go beyond volumizing for natural-looking results.^30-33 Our HA is minimally modified and our innovative manufacturing process preserves its biocompatibility while creating individual products designed for a specific purpose.^34-37 Powered by NASHA^®, NASHA HD, OBT™ and SB-NASHA™ technologies, Restylane offers gels with the highest firmness to the highest flexibility, enabling personalized treatments that deliver structural support, natural-looking results, and a healthy glow.^38-41 Trusted for almost three decades, our HA gels work in sync with your skin for 100% natural-looking results.^30,42,43

About Relfydess (RelabotulinumtoxinA)
Pioneered by Galderma, Relfydess is the first and only ready-to-use liquid neuromodulator created with PEARL Technology that is designed to preserve molecule integrity.¹⁴ PEARL Technology is designed to deliver a highly active, innovative, complex-free molecule, with up to 39% of patients seeing effects from day one and up to 75% of patients maintaining improvements for six months.^14,44,45 Relfydess is optimized for simple volumetric dosing, without reconstitution, to increase ease-of-use and help ensure consistent dose/volume every time.^46,47 It was entirely created and manufactured by Galderma to expand its neuromodulator portfolio as part of the broadest Injectable Aesthetics portfolio on the market. Relfydess received a marketing authorization in several markets. RelabotulinumtoxinA is an investigational drug product in the U.S. Authorization conditions may vary internationally.

About Galderma
Galderma (SIX: GALD) is the pure-play dermatology category leader, present in approximately 90 countries. We deliver an innovative, science-based portfolio of premium flagship brands and services that span the full spectrum of the fast-growing dermatology market through Injectable Aesthetics, Dermatological Skincare and Therapeutic Dermatology. Since our foundation in 1981, we have dedicated our focus and passion to the human body’s largest organ – the skin – meeting individual consumer and patient needs with superior outcomes in partnership with healthcare professionals. Because we understand that the skin we are in shapes our lives, we are advancing dermatology for every skin story. For more information: www.galderma.com.

References

1. Haddad A, et al. International consensus: Sculptra^®/Restylane^® Skinboosters™ for non-facial rejuvenation. Poster presented at IMCAS 2026; January 29-31, 2026; Paris, France.

2. Fabi SG, et al. Regenerative aesthetic effects of poly L-lactic acid treatment. Poster presented at IMCAS 2026; January 29-31, 2026; Paris, France.

3. Sculptra^®. EU Instructions for Use. 2025. Available online. Accessed January 2026.

4. Galderma. Data on File. MA-57540.

5. Nikolis A, et al. A Prospective, Multicenter Trial on the Efficacy and Safety of Poly-L-Lactic Acid for the Treatment of Contour Deformities of the Buttock Regions. J Drugs Dermatol. 2022;21(3):295–303. doi: 10.36849/JDD.5924.

6. Beleznay K, et al. Safety and Effectiveness of Poly-L-lactic acid (PLLA-SCA) for the Improvement in Appearance of Cellulite – A Pilot Study. Poster presented at the IMCAS World Congress; February 1-3, 2024; Paris, France.

7. Mazzuco R, et al. Clinical and Histological comparative outcomes after injections of Poly-L-Lactic Acid and Calcium Hydroxyapatite in arms – a split side study. J Cosmet Dermatol. 2022;21(12):6727–6733. doi: 10.1111/jocd.15356. Epub 2022 Sep 20.

8. Nikolis A, et al. A new NASHA-HD, high G’ hyaluronic acid (HA) injectable evaluated for chin treatment in combination with lower face and mid-face HA filler treatment. Poster presented at IMCAS 2026; January 29-31, 2026; Paris, France.

9. Rivers J, et al. Effectiveness and safety of Restylane^® Lyft™ Lidocaine for jaw-line definition: A 12-month randomized controlled study. Poster presented at IMCAS 2026; January 29-31, 2026; Paris, France.

10. Moradi A, et al. Effectiveness and safety of a hyaluronic acid skin quality injectable for the correction of wrinkles in the décolletage area. Poster presented at IMCAS 2026; January 29-31, 2026; Paris, France.

11. Nestor M. Safety and effectiveness of an OBT™ hyaluronic acid filler for temple hollowing treatment: a randomized, controlled, clinical investigation. Poster presented at IMCAS 2026; January 29-31, 2026; Paris, France.

12. Moradi A, et al. Objective image analysis of wrinkle morphology and dynamic skin strain in GLs and LCLs treated with relaBoNT-A in the RELAX and EXPRESSION trials. Poster presented at IMCAS 2026; January 29-31, 2026; Paris, France.

13. Nikolis A, et al. Preferences and experiences across biostimulatory poly-L-lactic acid’s reconstitution processes and injection criteria (PREP study). Poster presented at IMCAS 2026; January 29-31, 2026; Paris, France.

14. Shridharani SM, et al. Efficacy and safety of RelabotulinumtoxinA, a new ready-to-use liquid formulation botulinum toxin: Results from the READY-1 double-blind, randomized, placebo-controlled phase 3 trial in glabellar lines. Aesthet Surg J. 2024;44(12):1330-1340. doi: 10.1093/asj/sjae131.

15. Ascher B, et al. Consensus Recommendations on the Aesthetic Use of RelabotulinumtoxinA to Treat Upper Face Wrinkles. Poster presented at IMCAS 2026; January 29-31, 2026; Paris, France.

16. Fabi SG, et al. The potential role of biostimulators/dermal fillers to address menopause-related skin conditions. Poster presented at IMCAS 2026; January 29-31, 2026; Paris, France.

17. Galderma. Data on file. Menopause Patient Survey.

18. Waibel J, et al. Bulk RNA-seq Analysis of Poly-L-Lactic Acid (PLLA-SCA) vs Calcium Hydroxyapatite (CaHA-R) Reveals a Novel, Adipocyte Mediated Regenerative Mechanism of Action Unique to PLLA. Poster presented at ASDS 2024 Annual Meeting; October 17-20, 2024; Orlando, Florida, United States.

19. Waibel J, et al. Gene Analysis of Biostimulators: PLLA-SCA Triggers Regenerative Morphogenesis while CaHA-R Induces Inflammation upon Facial Injection. Poster presented at ASDS 2024 Annual Meeting; October 17-20, 2024; Orlando, Florida, United States.

20. Huth S, et al. Molecular Insights into the effects of PLLA_SCA on Gene Expression and Collagen Synthesis in Human 3D Skin Models Containing Macrophages. J Drugs Dermatol. 2024;23(4):285–288. doi: 10.36849/JDD.7791.

21. Galderma. Data on File. MA-46589.

22. Vleggaar D, et al. Consensus recommendations on the use of injectable poly-L-lactic-acid for facial and nonfacial volumization. J Drugs Dermatol. 2014;13(4 Suppl):s44–s51.

23. Widgegrow J, et al. A randomized, comparative study describing the gene signatures of poly-l-lactic acid (PLLA-SCA) and Calcium Hydroxyapatite (CaHA) in the treatment of nasolabial folds. Poster presented at IMCAS World Congress; February 1-3, 2024. Paris, France.

24. Duracinsky M, et al. Safety of poly-L-lactic acid (New-Fill^®) in the treatment of facial lipoatrophy: a large observational study among HIV-positive patients. BMC Infect Dis. 2014;14(474). doi: 10.1186/1471-2334-14-474.

25. Zhang S and Duan E. Fighting against Skin Aging: The Way from Bench to Bedside. Cell Transplant. 2018;27(5):729–738. doi: 10.1177/0963689717725755.

26. Shuster S, et al. The influence of age and sex on skin thickness, skin collagen and density. Br J Dermatol. 1975;93(6):639-43. doi: 10.1111/j.1365-2133.1975.tb05113.x.

27. Zarbafian M, et al. The emerging field of regenerative aesthetics—where we are now. Dermatol Surg. 2022;48:101–108. doi: 10.1097/DSS.0000000000003239.

28. Fabi S, et al. 24-month clinical trial data on effectiveness and safety after correction of cheek wrinkles using a biostimulatory poly-L-lactic acid injectable implant. Poster presented at IMCAS World Congress; January 26-28, 2023; Paris, France.

29. Goldberg D, et al. Single-arm study for the characterization of human tissue response to injectable poly-L-lactic acid. Dermatol Surg. 2013;39(6):915–922. doi: 10.1111/dsu.12164.

30. Di Gregorio C, et al. 25+ years of experience with the Restylane portfolio of injectable HA fillers for facial aesthetic treatment. E-poster presented at AMWC; March 27-29, 2024; Monaco.

31. Nikolis A, et al. The role of clinical examination in midface volume correction using hyaluronic acid fillers: should patients be stratified by skin thickness? Aesthet Surg J Open Forum. 2020;2(1):1–12. doi: 10.1093/asjof/ojaa005.

32. Talarico S, et al. High patient satisfaction of a HA filler producing enduring full-facial volume restoration: an 18- month open multicenter study. Dermatol Surg. 2015;41:1361–1369. doi: 10.1097/DSS.0000000000000549.

33. Restylane. U.S. Instructions for use. Available online. Accessed January 2026.

34. Edsman K, et al. Gel properties of hyaluronic acid dermal fillers. Dermatol Surg. 2012;38:1170–1179. doi: 10.1111/j.1524-4725.2012.02472.x.

35. Galderma. Data on file. MA-58650. Degree of modification of HA fillers.

36. Seo K. Facial volumization with fillers. Springer. 2021;29–83. https://doi.org/10.1007/978-981-33-6212-3_2.

37. Kablik J, et al. Comparative physical properties of hyaluronic acid dermal fillers. Dermatol Surg. 2009:35S(1):302–312. doi: 10.1111/j.1524-4725.2008.01046.x.

38. Galderma Data on file. MA-56724. X-strain and G’ including Shaype.

39. Nikolis A, et al. Effectiveness and Safety of a New Hyaluronic Acid Injectable for Augmentation and Correction of Chin Retrusion. J Drugs Dermatol. 2024;23(4):255–261. doi: 10.36849/JDD.8145.

40. Öhrlund Å et al. Differentiation of NASHA and OBT Hyaluronic Acid Gels According to Strength, Flexibility, and Associated Clinical Significance J Drugs Dermatol. 2024;23(1):1332–1336. doi: 10.36849/JDD.7648.

41. Belmontesi M et al. Injectable Non-Animal Stabilized Hyaluronic Acid as a Skin Quality Booster: An Expert Panel Consensus J Drugs Dermatol. 2018;17(1):83–88.

42. Solish N, et al. Dynamics of HA fillers formulated to maintain natural facial expression. J Cosmet Dermatol. 2019;18(3):738-746. doi: 10.1111/jocd.12961.

43. Philipp‐Dormston WG, et al. Perceived naturalness of facial expression after HA filler injection in nasolabial folds and lower face. J Cosmet Dermatol. 2020;19(7):1600-1606. doi: 10.1111/jocd.13205.

44. Ablon G, et al. Treatment of lateral canthal lines with RelabotulinumtoxinA, an investigational liquid botulinum toxin: clinical efficacy and safety results from the READY-2 phase 3 trial. Toxicon. 2024;237(1):107353. doi: 10.1026/j.toxicon.2024.107353.

45. Relfydess^®. EU Summary of Product Characteristics.

46. Sundberg AL and Stahl U. Relabotulinum toxin - a novel, high purity BoNT-A1 in liquid formulation. Presented at TOXINS; January 16-17, 2021; virtual meeting.

47. Do M, et al. Purification process of a complex-free highly purified botulinum neurotoxin type A1 (BoNT-A1) - relabotulinumtoxinA. Presented at TOXINS; July 27-30, 2022; Louisiana, United States.

View source version on businesswire.com: https://www.businesswire.com/news/home/20260121547346/en/